Page last updated: 2024-11-11

tenofovir diphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5481180
CHEMBL ID1236349
SCHEMBL ID14354588
MeSH IDM0587782

Synonyms (21)

Synonym
CHEMBL1236349 ,
pmpa diphosphate
tenofovir diphosphate
[(1r)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-[hydroxy(phosphonooxy)phosphoryl]oxy-phosphinic acid
tenofovir-dp
pmpapp
tfvtp
9-[(2r)-2-({[(phosphonooxy)(hydroxyphosphoryl)oxy](hydroxyphosphoryl)}methoxy)propyl]purine-6-ylamine
166403-66-3
[2-(6-amino-9h-purin-9-yl)-1-methylethoxy]methyl-triphosphate
tenofovir-diphosphate
tnv ,
[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-[hydroxy(phosphonooxy)phosphoryl]oxyphosphinic acid
SCHEMBL14354588
tenofovirdiphosphate
DTXSID70420498
AKOS027326734
bdbm50483421
Q27466645
HY-136548
CS-0130991

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In rats, systemic and local findings were considered not adverse due to their low severity and reversibility; therefore, the "no observed adverse effect level" (NOAEL) was set at 1,000 μg/kg/day."( A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
Alessi, T; Feldman, PL; Felx, M; Jain, R; Roller, S; Shelton, J; Singh, R; Wang, Y; Yang, B; Zane, D, 2021
)
0.62
" Consistent with previous findings, we observed adverse local toxicity and necrosis near the tenofovir alafenamide implant site."( Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
Dobard, C; García-Lerma, JG; Gary, J; Gatto, G; Heneine, W; Holder, A; Johnson, L; Khalil, G; Krovi, A; Li, L; Luecke, E; Massud, I; Mills, P; Mitchell, J; Nishiura, K; Pan, Y; Ruone, S; van der Straten, A, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" Increasing epithelial thickness delayed initial TFV delivery to stroma and its decline: tmax increased but AUC at 24 hours was not significantly altered."( Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
Gao, Y; Katz, DF, 2013
)
0.39
"The objective of this analysis was to develop and qualify a population pharmacokinetic model describing plasma tenofovir (TFV) concentrations and tenofovir-diphosphate (TFV-DP) concentrations in peripheral blood mononuclear cell (PBMC) in healthy women volunteers from the MTN-001 clinical trial, an open label 3-way crossover study of oral tenofovir disoproxil fumarate 300 mg tablet, TFV 1% vaginal gel, or both."( Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.
Burns, RN; Chaturvedula, A; Hendrix, CW, 2015
)
0.42
" Although colonic biopsies should be collected in the absence of medium for accurate TFV concentrations, the presence of medium does not significantly impact TFV-DP-dependent pharmacokinetic or pharmacodynamic assays."( Short Communication: Specimen Processing Impacts Tissue Tenofovir Pharmacokinetic Measurements.
Bakshi, RP; Breakey, J; Fuchs, EJ; Jois, B; Manohar, M; Marzinke, MA, 2018
)
0.48
"In this study of 14 days each of vaginal and rectal application of TFV reduced-glycerin 1% gel, we found only a small degree of cross-compartment distribution of TFV in RF and vaginal fluids and no pharmacodynamic activity in ex vivo testing."( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018
)
0.48
" Its clinical pharmacokinetic profile and influence on the cellular pharmacology of tenofovir diphosphate have not been reported."( Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.
Alexander, K; Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Ellison, L; Hosek, S; Huhn, GD; Ibrahim, ME; Kerr, BJ; Kiser, JJ; MaWhinney, S; McHugh, C; Tilden, S, 2019
)
0.97
"Tenofovir monoester Cmax and AUC0-4 were 59."( Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.
Alexander, K; Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Ellison, L; Hosek, S; Huhn, GD; Ibrahim, ME; Kerr, BJ; Kiser, JJ; MaWhinney, S; McHugh, C; Tilden, S, 2019
)
0.74

Bioavailability

ExcerptReferenceRelevance
" An adherence adjustment was included to account for nonadherence by explicitly modeling a bioavailability parameter on the previous day's dose."( Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.
Burns, RN; Chaturvedula, A; Hendrix, CW, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
"73 log10 copies per milliliter, including a dose-response relationship for viral load decrease up to 25 mg."( Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013
)
0.39
" This may translate into greater antiviral efficacy, a higher barrier to resistance, and an improved safety profile relative to TDF, supporting further investigation of TAF dosed once daily in HIV-infected patients."( Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013
)
0.39
" Knowledge of concentrations of Tenofovir and its active form Tenofovir diphosphate, at putative sites of anti-HIV functioning, is central to understanding trial outcomes and design of products and dosage regimens."( Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
Gao, Y; Katz, DF, 2013
)
0.63
" Thus contrasts predicted by this model can inform design of gels and dosage regimens in clinical trials, and interpretation of PK data."( Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
Gao, Y; Katz, DF, 2013
)
0.39
" A control group (n=34) received no drug, a second group (n=6) received oral tenofovir disoproxil fumarate/emtricitabine 3 days before each virus challenge and a third group (n=6) received the same dosing plus another dose 2 h after virus challenge."( Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.
Anderson, PL; Bushman, LR; García-Lerma, JG; Glidden, DV; Heneine, W, 2014
)
1.85
"After tenofovir alafenamide dosing in vivo , tenofovir-dp was unquantifiable in most tissues (91%) although cervical and vaginal epithelial cells efficiently formed tenofovir-dp from tenofovir alafenamide in vitro ."( Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.
Cottrell, ML; Emerson, CW; Garrett, KL; Gay, C; Kashuba, ADM; McCallister, S; Peery, A; Prince, HMA; Rooney, JF; Schauer, A; Sykes, C, 2017
)
0.46
" We conducted a prospective, randomized, crossover pharmacokinetic study of TFV-DP in DBS during 33%, 67%, or 100% of daily dosing under directly observed therapy (DOT)."( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
Anderson, PL; Buchbinder, S; Bushman, LR; Campbell, K; Castillo-Mancilla, JR; Gardner, EM; Ibrahim, M; Kiser, JJ; Liu, AY; MaWhinney, S; McHugh, C; Morrow, M; Seifert, SM; Wagner, T, 2018
)
0.48
" Secondary outcomes included DBS TFV-DP concentrations of >1246 fmol/punch (ie, near-perfect adherence) and plasma FTC >350 ng/mL (consistent with dosing within the past 24 hours)."( Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.
Anderson, P; Best, BM; Blumenthal, J; Collins, D; Corado, K; Daar, ES; Dubé, MP; Ellorin, E; Haubrich, R; Jain, S; Milam, J; Moore, DJ; Morris, SR; Sun, X; Young, J, 2018
)
0.48
" At week 12, iTAB was superior to SoC for dosing in past 24 hours by plasma FTC (47."( Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.
Anderson, P; Best, BM; Blumenthal, J; Collins, D; Corado, K; Daar, ES; Dubé, MP; Ellorin, E; Haubrich, R; Jain, S; Milam, J; Moore, DJ; Morris, SR; Sun, X; Young, J, 2018
)
0.48
"MTN-014 was a phase 1, cross-over, randomized sequence trial comparing the cross-compartment pharmacokinetics and pharmacodynamics of daily TFV reduced-glycerin 1% gel after 14 days each of rectal and vaginal application, with directly observed dosing and a 6-week washout period between phases."( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018
)
0.48
" TFV and TFV diphosphate (TFV-DP) were detected in most samples collected from the dosing compartment."( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018
)
0.48
" Although high TFV concentrations in the dosing compartment may be protective, low cross-compartment tissue concentrations are not likely to be protective."( Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Balar, B; Dai, JY; Dezzutti, CS; Galaska, B; Hendrix, CW; Justman, JE; Kunjara Na Ayudhya, RP; Levy, L; Marzinke, MA; McGowan, I; Mushamiri, I; Nair, GL; Pan, Z; Piper, JM; Schwartz, JL, 2018
)
0.48
" Using a murine model, we compared the plasma and tissue pharmacokinetics of TFV and various TFV prodrugs, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and hexadecyloxypropyl tenofovir (CMX157), after dosing as enema formulations with varying osmolality and ion content."( Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
Bensouda, S; Cone, RA; Date, AA; Ensign, LM; Fuchs, EJ; Gumber, S; Hanes, J; Hendrix, C; Hoang, T; Marzinke, M; Ortiz, JO; Rohan, L; Villinger, F; Xiao, P; Young, TW, 2019
)
0.51
" It has been proven that HIV infection can be prevented by daily dosing of emtricitabine and tenofovir disoproxil fumarate."( Direct quantitation of tenofovir diphosphate in human blood with mass spectrometry for adherence monitoring.
Anderson, PL; Bushman, LR; Cooks, RG; Ouyang, Z; Pandey, S; Pu, F, 2020
)
0.87
" Recent dosing measures include antiretroviral levels in plasma or urine, as well as emtricitabine-triphosphate in dried blood spots (DBS) for those on tenofovir-emtricitabine-based therapy."( Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.
Anderson, PL; Castillo-Mancilla, J; Chai, PR; Gandhi, M; Haberer, JE; Spinelli, MA, 2020
)
0.56
"TAF-DBS was a randomized, crossover clinical study of TFV-DP in DBS, following directly observed dosing of 33%, 67%, or 100% of daily TAF (25 mg)/FTC (200 mg)."( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J, 2020
)
0.56
" Together, these moieties provide complementary measures of cumulative adherence and recent dosing for TAF/FTC."( Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Anderson, PL; Brooks, KM; Bushman, LR; Castillo-Mancilla, J; Ibrahim, ME; Kiser, JJ; MaWhinney, S; McCallister, S; McHugh, C; Morrow, M; Yager, J, 2020
)
0.56
"TGM and TGW on at least 6 months of stable sex hormone therapy containing testosterone or estradiol (respectively) were enrolled in a 4-week study of directly observed dosing of daily oral coformulated emtricitabine and tenofovir disoproxil fumarate (FTC/TDF)."( Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
Anderson, PL; Bhasin, S; Defechereux, PA; Deutsch, MB; Glidden, DV; Grant, RM; O'Neal, J; Pellegrini, M; Sevelius, J; Yager, J; Yu, M, 2021
)
0.93
" We observed significant dose-response relationships between number of HIV risk factors and PrEP drug concentrations."( Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
Anderson, PL; Bekker, LG; Celum, C; Chirenje, ZM; Delany-Moretlwe, S; Donnell, D; Hosek, S; Marzinke, MA; Mgodi, N; Velloza, J, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (2)

PathwayProteinsCompounds
Tenofovir Action Pathway05
Tenofovir Metabolism Pathway45

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Kd4.30000.00062.40599.8000AID572771
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID572772Ratio of Kpol to Kd for HIV1 reverse transcriptase2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572771Binding affinity to HIV1 reverse transcriptase2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572770Activity at HIV1 reverse transcriptase measured after 30 mins2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572773Selectivity, ratio of Kpol to Kd for dATP to Kpol to Kd for compound at HIV1 reverse transcriptase2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (88)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (1.14)29.6817
2010's45 (51.14)24.3611
2020's42 (47.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.95 (24.57)
Research Supply Index4.74 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials25 (28.09%)5.53%
Reviews2 (2.25%)6.00%
Case Studies1 (1.12%)4.05%
Observational4 (4.49%)0.25%
Other57 (64.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]